Phase II trials

Compound Type of drug Tumour type
Xentuzumab (BI 836845) IGF ligand monoclonal antibody Metastatic breast cancer (oestrogen-receptor positive)
BI 1361849 Immunotherapeutic cancer mRNA vaccine Non-small cell lung cancer
BI 836826 CD37 monoclonal antibody

Chronic lymphocytic leukaemia

Non-Hodgkin lymphoma (relapsed or refractory)


This is an investigational compound and has not yet been fully approved. Its safety and efficacy has not yet been fully established.

IGF, Insulin-like growth factor; mRNA, messenger ribonucleic acid.

Last updated August 2016.